An observational study in Kidney Failure, Chronic, Peritoneal Dialysis Complication and Transplantation, sponsored by Heidelberg University. Recruiting at 26 sites in 15 countries. Open to participants aged 1 Day to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by Heidelberg University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 109 studies in Kidney Failure, Chronic with a site in Germany — 9 open to participants now, 15 under way, 4 of them phase 3. Kidney Failure, Chronic · Germany.
Among the 109 studies in Kidney Failure, Chronic with a site in Germany, this one is the 8th largest by planned enrollment of the 23 observational ones that give a count, is one of 5 that started in 2011, is one of 23 observational ones, reaches primary completion later than 8 of the 14 other live ones, and was the 51st registered.
2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.
Browse Kidney Failure, Chronic studies →9 of the 109 studies in Kidney Failure, Chronic with a site in Germany are open now. Recruiting first, the newest first:
CSL Behring · Sites in Germany, United States, Argentina and 32 more countries
Ages 18+
W.L.Gore & Associates · Sites in Germany, Italy, United Kingdom
Ages 18+
Iperboreal Pharma Srl · Sites in Germany, Denmark, Italy and 3 more countries
Ages 18+
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · Sites in Germany, United States, France and 7 more countries
University of Sydney · Sites in Germany, Australia, Canada and 3 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 1 Day to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
109 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 16 · Phase 3 26 · Phase 4 9
First in 1994; this study’s year is marked. 5 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 120 across 445 observational studies indexed under Kidney Failure, Chronic.
Median enrollment 81 across the 86 interventional studies, 119 across the 23 observational. Of the 85 that completed or were terminated, 26 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
65 of 109 have an industry lead sponsor. The 10 most frequent:
Heidelberg University is the lead sponsor of 287 studies on the registry; 18 are open to participants now.
Heidelberg University has 5 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
4 of the studies in Kidney Failure, Chronic with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03994471Phase 3Iperboreal Pharma SrlEfficacy and Safety of XyloCore Peritoneal Dialysis Solution. | 2026-12-31 |
| NCT05970172Phase 3Astellas Pharma Global Development, Inc.A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease | 2027-10-30 |
| NCT02823821University of SydneyRandomised Evaluation of Sodium Dialysate Levels on Vascular Events | 2026-12 |
| NCT05846581W.L.Gore & AssociatesRegistry of GORE® ACUSEAL Vascular Graft in Dialysis Access | 2027-10-27 |
Add all 4 to your calendar (.ics) → With an account.
Among the 109 studies in Kidney Failure, Chronic with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Within few years the peritoneal membrane of adult peritoneal dialysis (PD) patients undergoes substantial morphological transformation, including progressive fibrosis, vasculopathy and neoangiogenesis. Ultrafiltration capacity steadily declines and ultimately results in PD failure. In children, peritoneal biopsies demonstrating PD associated alterations have not yet been obtained. They, however, should be particularly informative, since secondary tissue and vascular pathology related to ageing or diabetes is absent.
An international, prospective peritoneal membrane biopsy study in children on PD will therefore be performed. Biopsies will be obtained at time of PD catheter insertion, on occasion of intercurrent abdominal surgery (e.g. hernia repair, catheter exchange) and at time of renal transplantation. Quantitative histomorphometry and tissue protein expression analyses will be correlated with time integrated PD treatment modalities and functional characteristics as well as inflammatory and cardiovascular comorbidity surrogate parameter. Blood will be obtained during clinical routine sampling. Biopsies will be obtained during clinically indicated operations, without substantially increasing operation time and associated surgical risks. The detailed histomorphometry of the PD membrane will give additional information, potentially impacting on the individual PD regime.
3/2018: The analyses of the pediatric PD biopsy demonstrated early and major transformation of the peritoneal membrane with neutral pH low GDP fluids, and significant vasculopathy already in children with CKD stage 5, further progressing with PD. The underlying mechanisms are partly understood, only. In view of these major findings and the numerous open questions, collection of biosamples will be continued in children and also in adult PD patients. The following questions will be addressed: Molecular counterparts of peritoneal semi-permeability, solute and water transport (beyond AQP1), pathomechanisms and molecular and functional impact of peritoneal transformation with low and high GDP fluids, and the respective pathomechanisms and molecular and functional impact of vascular disease in CKD and with different PD fluids. The impact of renal transplantation following PD will be assessed in a subgroup of patients with tenckhoff catheter removal several weeks after transplantation and a functioning graft.
Please see study protocol and
http://www.pedpd.org
See eligibility data
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
'Biopsy sampling': Peritoneal biopsies without kidney disease, i.e. diseases not related to the kidney and not affecting the peritoneum. This group is accomplished.
Samples will obtained from patients with chronic kidney disease stage 5 (at time of catheter Insertion)
Procedure: biopsy sampling
Patients on PD with different PD fluids and intercurrent abdominal surgery and at time of renal transplantation.
Procedure: biopsy sampling
Samples will also be collected and analysed from patients with renal transplantation after PD at time of and tenckhoff catheter removal several weeks after Tx or other intercurrent abdominal surgery.
Procedure: biopsy sampling
Two parietal peritoneal samples, each 1 cm² x 0.3 cm in depth and three omental tissue samples, each 1 cm² in size will be obtained. Biopsy sampling will be performed in all groups. This is an observational not an interventional trial.
Peritoneal vasculopathy (lumen vessel ratio)
Digital quantification of degree of vasculopathy, i.e the lumen vessel ratio. Healthy children have a L/V ratio of about 0.7. lower values represent vasculopathy with lumen narrowing, 0 is complete obliteration of the vessel. This measurements will be accompanied by molecular analysis of pathomechanisms (including omics Technology)
Time frame: Two years (Mean PD treatment time)
Number of vessels per peritoneal membrane area (per mm²)
Digital histomorphometry of small vessel density per mm² submesothelial section area analysed.
Time frame: at time of catheter insertion, intercurrent abdominal surgery and at time of renal transplantation
Submesothelial thickness (µm)
Digital imaging analysis of submesothelial thickness as a marker of peritoneal fibrosis (distance between mesothelium and adjacent muscle/adipos tissue)
Time frame: 2 years (average PD duration)
Submesothelial lymphocyte, macrophage, MMT cell count
Quantification of peritoneal leucocyte Infiltration, i.e. number of CD45 positive lymphocytes and CD68 positive macrophages per mm² of submesothelial section area . The number of cells that underwent mesothelial-mesenchymal transition per mm² submesothelial section are quantified by immunohistochemical co-staining of mesothelial and fibroblast marker (cytokeratin and FSP1).
Time frame: 2 years (mean PD duration)
Peritoneal VEGF and pSMAD abundance
Key cytokines involved in peritoneal membrane transformation will be measured immunohistochemically. These are VEGF and TGF-beta induced p-SMAD (%positive area per section area analysed).
Time frame: 2 years (mean PD duration)
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Started Feb 2011 (actual). Primary completion is estimated for Oct 2028, 212 months after the start.
Of 132 non-industry observational studies under Kidney Failure, Chronic, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 62. This study's planned 212 months is above that.
Counting every sponsor, half of 151 studies reached it within 29 months; a quarter within 11 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.